Background: Lovastatin (LOV), a highly lipophilic drug associated with poor oral bioavailability,
belongs to the class of cholesterol lowering drugs. With the objective to improve the
solubility and to attain sustained release, solid lipid nanoparticles (SLNs) have been formulated.
Method: Lovastatin loaded solid lipid nanoparticles (LOV-SLNs) were prepared by pre-emulsion
and probe sonication method. LOV-SLNs were studied by Atomic Force Microscope (AFM), Differential
Scanning Calorimetry (DSC) and Reverse Phase High Performance Liquid Chromatography
Result: The particle size and zeta potential of optimized formulation were found to be 169.4±14.1
nm and -24.1 mV, respectively.
Conclusion: The in vitro drug release studies confirmed the sustained release nature of the formulation
and revealed that the drug released from the prepared LOV-SLNs is the combination
of dissolution, diffusion and erosion. The data obtained from in vitro dissolution study show
that LOV-SLNs is a promising colloidal system which could significantly improve the oral bioavailability
of LOV by improving the solubility.